CSLLY News and Press, CSL Ltd ADR From 08/13/21

July was a better month for the Project $1M portfolio, with the portfolio returning 2%, but still finishing down vs. S&P 500. Atlassian spared the portfolio a much worse finish and was the star for the month. Chinese regulatory risk reared its ugly head, significantly impactin...

The European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Force Has Strongly Recommended Subcutaneous Immunoglobulin (SCIg) for CIDP Maintenance Treatment The updated guideline empowers physicians with the confidence to expand the treatment options prescrib...

FDA Approves New BERINERT® (C1 Esterase Inhibitor, Human (Intravenous)) Administration Kit for Increased Patient Convenience PR Newswire KING OF PRUSSIA, Pa. , Aug. 3, 2021 /PRNewswire/ -- CSL Behring , a global biotherapeutics leader received U.S. F...

Seqirus Presents New Safety Data Demonstrating Safety of Cell-Based Seasonal Influenza Vaccine on Pregnancy Outcomes PR Newswire SUMMIT, N.J. , July 30, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL),...

Seqirus Begins Shipping Portfolio of Innovative Vaccines for the 2021/22 U.S. Influenza Season PR Newswire SUMMIT, N.J. , July 27, 2021 /PRNewswire/ -- Seqirus offers a differentiated portfolio of influenza vaccines, including FLUCELVAX ® QUADRIVAL...

It was a tough month for the Project $1M portfolio in May, and continues a trend of negative performance against the S&P500 in 2021. The portfolio has been helped by strong performance in Alphabet and Facebook so far this year. Mercadolibre particularly struggled in May and wa...

Seqirus Co-Authors First Study to Assess Simultaneous Administration of Seasonal Influenza Vaccine and COVID-19 Vaccine Candidate PR Newswire SUMMIT, N.J. , June 14, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a division of CSL Limit...

Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) To Be Covered Under Medicare Part B Effective July 18, Improving Access and Reducing Out-of-Pocket Costs for CIDP Patients Hizentra will be covered under the same Medicare benefit category as intravenous immune glo...

CSL Limited recently closed a license agreement for a haemophilia B gene therapy candidate which is positive, but there are still risks associated with competition and regulatory approvals. The company's near-term outlook is mixed, with the potential upside of increased influenza...

New Meta-Analysis of Patients with Acute Coronary Syndrome Shows Nearly Half of Recurrent Major Adverse Cardiovascular Events at One Year Occur Within the First 90 Days Findings signal need for novel treatment strategies to provide more protection during this high-risk, 90-day p...